Clinical trial NCT00637611: Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit
Official title: Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Seasonal Allergic Rhinitis
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-03-18
Enrollment: 1010
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo. Secondary objectives are to compare the safety and efficacy of fexofenadine hydrochloride 180 mg, montelukast sodium 10 mg, and placebo


Eligibility criteria: Inclusion Criteria:

* Male and female subjects, 15 years of age or older
* History of seasonal allergic rhinitis (SAR) during the fall pollen season, for at least the previous 2 years
* History of having a positive response to antihistamines for symptoms of SAR
* Must be skin test positive to ragweed within the last 15 months with at least a moderate reaction as defined by a wheal 7 mm greater than the diluent wheal after intradermal skin test or a wheal 5 mm greater than the diluent wheal after skin prick test. A skin test performed in the previous 15 months may be used to qualify the patient if it was performed at the investigator's site and recorded in the subject's medical record
* All females must have negative urine pregnancy test at screening visit
* Willing and able to adhere to visit schedules and all study requirements

Exclusion Criteria:

* Clinically significant medical condition (such as cardiovascular, hepatic, neurologic, hematological, renal, gastrointestinal, endocrine, or other major systemic disease), which, in the judgment of the investigator, might interfere with the study, require treatment or make implementation of the protocol or interpretation of the study results difficult
* Asthma that requires treatment with medication other than an inhaled, short-acting beta agonist or asthma that will be exacerbated by exposure to ragweed pollen
* Pregnancy or breast-feeding
* History of hypersensitivity to the study medications or to drugs with similar chemical structures
* Nasal structural abnormalities, including large nasal polyps or marked septal deviation, that significantly interfere with nasal air flow
* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol
* Upper or lower respiratory infection within 14 days of the first priming visit
* Diagnosis of sinusitis within 30 days of the first priming visit
* Immunotherapy, except those on a constant dose of immunotherapy that will be maintained throughout the study
* Treatment with any investigational drug in the last 30 days before study entry
* Recent history of drug or alcohol abuse
* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
* Unlikelihood to comply with protocol such as those with uncooperative attitude or the inability to return for follow-up visits or to complete the study
* Subjects who were randomized into this trial will not be eligible to participate in another fexofenadine hydrochloride 180 mg vs montelukast sodium 10 mg onset of action study (planned to be conducted in 2003)
* Subjects who are research employees or relatives of study site staff involved in this study or those who have or will read the protocol

Primary outcomes:
measure: To determine the efficacy and onsets of action of single-dose fexofenadine hydrochloride 180 mg and montelukast sodium 10 mg relative to placebo in the treatment of subjects with moderately severe seasonal allergic rhinitis (SAR) in a controlled setting.
Secondary outcomes:
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis
state: New Jersey
Study officials:
affiliation: Sanofi
name: Phyllis Diener
role: STUDY_DIRECTOR
References: